Your browser doesn't support javascript.
loading
The pharmacokinetics of risperidone in humans: a summary.
Heykants, J; Huang, M L; Mannens, G; Meuldermans, W; Snoeck, E; Van Beijsterveldt, L; Van Peer, A; Woestenborghs, R.
Afiliação
  • Heykants J; Department of Drug Metabolism and Pharmacokinetics, Janssen Research Foundation, Beerse, Belgium.
J Clin Psychiatry ; 55 Suppl: 13-7, 1994 May.
Article em En | MEDLINE | ID: mdl-7520903
ABSTRACT
Risperidone is rapidly and completely absorbed after oral administration; less than 1% is excreted unchanged in the feces. The principal metabolite was found to be 9-hydroxyrisperidone. Hydroxylation of risperidone is subject to the same genetic polymorphism as debrisoquine and dextromethorphan. In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers. However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the "active fraction" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers. We found that risperidone exhibited linear elimination kinetics and that steady state was reached within 1 day for risperidone and within 5 days for the active fraction.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Piperidinas / Antipsicóticos / Isoxazóis Limite: Aged / Animals / Humans / Male Idioma: En Revista: J Clin Psychiatry Ano de publicação: 1994 Tipo de documento: Article País de afiliação: Bélgica
Buscar no Google
Base de dados: MEDLINE Assunto principal: Piperidinas / Antipsicóticos / Isoxazóis Limite: Aged / Animals / Humans / Male Idioma: En Revista: J Clin Psychiatry Ano de publicação: 1994 Tipo de documento: Article País de afiliação: Bélgica